Cantargia publishes interim report for first quarter 2021
Cantargia AB’s (”Cantargia”) interim report for first quarter 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the first quarter · The first patient with pancreatic cancer started treatment in the extension part of the CANFOUR study. · An application was submitted to start a new phase Ib clinical study on combination treatment with CAN04 and FOLFIRINOX in pancreatic cancer. · Positive preclinical safety and efficacy results were presented for the CAN10 antibody. Significant events after the end of the period